Figure 1: Screen for antineoplastic drugs and therapeutic targets in PTCL cell lines. | Nature Communications

Figure 1: Screen for antineoplastic drugs and therapeutic targets in PTCL cell lines.

From: THZ1 targeting CDK7 suppresses STAT transcriptional activity and sensitizes T-cell lymphomas to BCL2 inhibitors

Figure 1

(a) Screen setup and results. (b) Extended target validation in four PTCL cell lines (top). Drugs that showed >50% decrease in viability at <100 nM are shown as filled squares. (c) Growth inhibitory concentration 50% (GI50, Y axis) for nine compounds (shown on bottom) in an extended panel of six PTCL cell lines.

Back to article page